IgM-Multimerized Single-Domain Antibodies for ROR1 Binding Avidity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ROR1-related conditions, such as certain cancers, lack effective targeting and binding capabilities due to limitations in antibody function and specificity, particularly in multivalent binding and tissue distribution.
Innovation Solution
Development of IgM-multimerized single-domain antibodies that bind ROR1, incorporating a multimerizing IgM Fc region and specific single-domain antibodies like Nb11 WT, Nb14 WT, huNb14 Lo1, huNb14 Mid1, and huNb14 Hi2, which form pentameric structures for enhanced binding avidity and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional monoclonal antibodies are used for ROR1 targeting, then basic binding capability is achieved, but binding avidity and therapeutic efficacy are insufficient
Solution Approach 1:
The patent combines multiple single-domain antibody units with an IgM Fc region to form a multimerized antibody structure. This merging of multiple binding units into a single functional entity increases binding avidity through multivalent interaction with ROR1, while the modular design maintains manageable structural complexity
Solution Approach 2:
The antibody is segmented into distinct functional modules: single-domain antibody binding units and an IgM Fc multimerizing region. This segmentation allows independent optimization of binding capability and multimerization function, resolving the contradiction between enhanced avidity and structural complexity
2Productivity
If IgM-multimerized single-domain antibodies are developed, then binding avidity and tissue distribution are enhanced, but structural complexity increases
Solution Approach 1:
The IgM Fc region serves multiple functions simultaneously: it enables multimerization of the antibody units, provides structural stability, and facilitates enhanced tissue distribution. This multi-functionality allows the structure to achieve improved therapeutic efficacy without proportionally increasing complexity
Solution Approach 2:
The antibody construct combines different protein domains (single-domain antibody units and IgM Fc region) into a composite molecular structure. This composite design integrates the binding specificity of single-domain antibodies with the multimerization and distribution advantages of IgM structures, achieving enhanced therapeutic efficacy while maintaining rational structural organization
Data Source
AI summary
IgM-multimerized single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The IgM-multimerized single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions and can be conjugated to form multi-domain binding molecules or antibody conjugates.